http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2712454-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84b1cabe3b04744259e561cc2b0c8de2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39f8f8fef6551fbec5a9761e65f14d21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eabc18c63f6093af3ea26748503cbdd6 |
| publicationDate | 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2712454-C1 |
| titleOfInvention | Method of treating renal cell carcinoma |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, and aims at treating renal cell carcinoma. Combination of preparations is administered to a patient: 3 times a week in amount of 12000000 ME per day and Endoxane. Endoxane is orally administered in amount of 50 mg a day and additionally subcutaneously in amount of 200,000 units a day, twice a week. Computed tomography is performed every 8 weeks. If observing X-ray signs of disease progression, the levels of spontaneous production of IL-10 (X1), induced production of IL-8 (X2), spontaneous production of IL-4 (X3), induced TNF-α (X4) and absolute concentration of natural killers with T-lymphocyte receptors CD3+CD16+56+(X5). Discriminant functions F1 and F2 are calculated from obtained values. If F1>F2 treatment is continued in previous mode. If F2>F1, the patient is transferred to sunitinib therapy. Between 8-week sunitinib cycles, 2-week pause is performed.EFFECT: invention enables improving survival rates in patients with renal cell carcinoma.1 cl, 13 tbl, 1 ex |
| priorityDate | 2019-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 200.